Status:
COMPLETED
Bioequivalence of Alprazolam Sublingual vs Oral Tablets
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Healthy
Eligibility:
All Genders
21-55 years
Phase:
PHASE1
Brief Summary
This study tests the assumption that the bioavailability of alprazolam from a new sublingual formulation is the same as that from a standard orally administered tablet.
Eligibility Criteria
Inclusion
- Healthy male or female subjects
- BMI 17.5 - 30.5
- Must provide informed consent
Exclusion
- Clinically significant disease
- Narrow angle glaucoma
- Positive drug screen
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT00860119
Start Date
August 1 2009
End Date
October 1 2009
Last Update
January 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Ahmedabad, Gujarat, India, 380 015